Advertisement

Targeted Oncology

, Volume 12, Issue 6, pp 839–840 | Cite as

Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

  • Arnaud Uguen
Letter to the Editor

Notes

Compliance with Ethical Standards

Funding

None.

Conflict of Interest

The author declares no conflict of interest.

References

  1. 1.
    Auliac JB, Monnet I, Dubos-Arvis C, et al. Non-small cell lung cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 study). Target Oncol. 2017;  https://doi.org/10.1007/s11523-017-0520-7.
  2. 2.
    Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9(3):295–306.CrossRefPubMedGoogle Scholar
  3. 3.
    Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26(1):238–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Lantuejoul S, Rouquette I, Blons H, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMedGoogle Scholar
  5. 5.
    Uguen A, Andrieu-Key S, Vergne F, et al. ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues. Oncol Rep. 2016;36(3):1427–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Antoine M, Chenard MP, Piton N, Sabourin JC. Recommandations SFP- AFAQAP pour le testing ALK dans les CBNPC- mai 2017. Société Française de Pathologie 2017;http://www.sfpathol.org/media/pdf/reco-alk-2017-sfp-afaqap-mai-2017.pdf.
  7. 7.
    van der Wekken AJ, Pelgrim R, ‘t Hart N, et al. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer. Clin Cancer Res. 2017;23:4251–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Dagogo-Jack I, Shaw AT. Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics? Oncologist. 2016;21(6):662–3.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.CHRU Brest, Department of PathologyBrestFrance
  2. 2.Inserm, U1078BrestFrance
  3. 3.Department of PathologyUniversity Hospital MorvanBrestFrance

Personalised recommendations